Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

Ian D. Davis, Weisan Chen, Heather Jackson, +25

Proceedings of the National Academy of Sciences

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà, +127

The Lancet Oncology

Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor +6

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m²) and the Currently Approved Dose (25 mg/m²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA

Mario A. Eisenberger, Anne-Claire Hardy-Bessard, Choung‐Soo Kim, +10

Journal of Clinical Oncology

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio, Karl D. Lewis, Lev Demidov, +136

The Lancet Oncology

MedicineMelanomaImmunologyClinical TrialsAdjuvant Vemurafenib +8

Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial

Wee Kheng Soo, Madeleine King, A. L. Pope, +3

The Lancet Healthy Longevity

Integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy.

Wee Kheng Soo, Madeleine King, A. L. Pope, +3

Journal of Clinical Oncology

Geriatric PsychiatryUsual CareCancer ManagementGeriatric MedicineOlder People +16

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park, +164

Annals of Oncology

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

Samantha Bowyer, Prashanth Prithviraj, Paul Lorigan, +17

British Journal of Cancer

The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.

Mark Shackleton, Ian D. Davis, Wendie Hopkins, +11

PubMed

ImmunologyImmunoeditingAdjuvant Flt3 LigandImmunotherapeuticsCd4 T Cell Responses +16

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee, +208

Journal of Clinical Oncology